论文部分内容阅读
探讨 5 - Fu用药途径 ,发挥其更好疗效。方法 :选择 13例消化道恶性肿瘤患者 ,术前用 5 - Fu腹腔灌注给药 ,3h后取腹腔液、门静脉血和外周循环血样 ,用我们建立的 HPL C检测方法 ,分析血样中 5 - Fu的含量。结果 :13例肿瘤病人体液样品中 5 - Fu浓度平均水平分别为腹腔液 (12 0 2 .0 2 6± 39.44 2 ) m g/ L,门静脉血 (2 99.882± 14.0 9) mg/ L,外周血 (7.5 12± 1.0 46 ) mg/ L。腹腔液比外周血高 16 0倍 ,门静脉血比外周血高 40倍。结论 :腹腔注射 5 - Fu后可在腹腔、门静脉维持高的药物浓度 ,进入体循环的量极少 ,对预防进展期消化道恶性肿瘤术后腹腔和肝脏转移有指导意义。
To explore the 5 - Fu route of administration to exert its better curative effect. Methods: Thirteen patients with gastrointestinal malignant tumor were selected and treated with 5 - Fu intraperitoneal perfusion before operation. Peritoneal fluid, portal vein blood and peripheral blood samples were obtained after 3 hours. The HPL C assay was used to analyze 5 - Fu Content. Results: The average levels of 5 - Fu in 13 tumor samples from patients with tumor were peritoneal fluid (122.02 ± 39.44 2) mg / L, portal vein blood (2 99.882 ± 14.0 9) mg / L, peripheral blood (7.5 12 ± 1.0 46) mg / L. Peritoneal fluid 16O times higher than peripheral blood, portal vein blood 40 times higher than peripheral blood. Conclusion: Intraperitoneal injection of 5 - Fu can maintain a high drug concentration in the abdominal cavity and portal vein and enter the systemic circulation in a very small amount. It is instructive to prevent peritoneal and hepatic metastasis of advanced malignant gastrointestinal cancer after operation.